-
-
-
-
-
-
-
PureTech publishes phase 2b trial results for lung fibrosis drug
-
-
-
-
-
-
-
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
-
-
-
-
-
-
-
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
-
-
-
-
-
-
-
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
-
-
-
-
-
-
-
PureTech Provides End of Year Report on Key Progress
-
-
-
-
-
-
-
PureTech Health's (PRTC) Akili Appoints Jon David as Chief Product Officer
-
-
-
-
-
-
-
resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
66,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

